Patent ID: 11932650
Assignee: TUFTS MEDICAL CENTER, INC.
Field: Organic fine chemistry (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A compound of Formula (I):, , or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein:
X is —O—, —S—, or —N(R6)—;
R3a, R3b, and R3c are each independently H or halogen;
(i) R1 is H, C1-10 alkyl, C2-10 alkenyl, or C2-8 alkynyl, each of which is optionally substituted with one or more R4, or alternatively, X and R1 combine to form —N3, R2 is C1-10 alkyl, C2-10 alkenyl, or C2-8 alkynyl, each of which is substituted with one or more R5, wherein up to 3 —CH2— units of R2 are each optionally replaced by an —O—, —S—, or —NR6—, provided that no adjacent —CH2— groups are replaced, or alternatively, R1 and R2 taken together with the atoms to which they are attached form a C5-10 heterocycloalkyl, C5-10 heterocycloalkenyl, or C5-10 heterocycloalkynyl ring, each of which is optionally substituted with one or more R4, and each instance of R4 is independently halogen, C1-5 alkyl, oxo, —OH, —OR6, —N3, —N(R6)2, —NH(C═O)R6, —NH(C═O)OR6, —NH(C═O)N(R6)2, —(C═O)R6, monocyclic heteroaryl of 5 or 6 ring atoms,, or
(ii): R1 is C1-10 alkyl, C2-10 alkenyl, or C2-8 alkynyl, each of which is optionally substituted with one or more R4, or alternatively, X and R1 combine to form —N3, R2 is C1-10 alkyl, C2-10 alkenyl, or C2-8 alkynyl, each of which is optionally substituted with one or more R5, wherein up to 3 —CH2-units of R2 are each optionally replaced by an —O—, —S—, or —NR6—, provided that no adjacent —CH2— groups are replaced, and each instance of R4 is independently halogen, C1-5 alkyl, —OH, —OR6, —N3, —N(R6)2, —NH(C═O)R6, —NH(C═O)OR6, —NH(C═O)N(R6)2, —(C═O)R6, monocyclic heteroaryl of 5 or 6 ring atoms,, each instance of R5 is independently halogen, oxo, —OH, —OR6, —N3, —N(R6)2,, each instance of R6 is independently H, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, —C1-5 alkyl-SiMe3, phenyl, or monocyclic heteroaryl of 5 or 6 ring atoms;
R7 is selected from the group consisting of hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted phenyl, optionally substituted monocyclic heteroaryl of 5 or 6 ring atoms, and optionally substituted acyl;
each of the substituents of the substituted aliphatic, substituted heteroaliphatic, substituted phenyl, substituted monocyclic heteroaryl of 5 or 6 ring atoms, and substituted acyl is independently selected from the group consisting of oxo, -halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6haloalkoxy, —OC1-C6 alkenyl, —OC1-C6 alkynyl, —C1-C6 alkenyl, —C1-C6 alkynyl, —OH, —CN, —CH2CN, —OP(O)(OH)2, —C(O)OH, —OC(O)C1-C6 alkyl, —C(O)C1-C6 alkyl, —OC(O)OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —S(O)2—C1-C6 alkyl, —S(O)2—C1-C6 haloalkyl, —C0-C6 alkylenyl-S(O)2NH2, —S(O)2NHC1-C6 alkyl, —S(O)2N(C1-C6 alkyl)2, —NHS(O)2C1-C6 alkyl, and —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), wherein each of the alkyl, alkoxy, haloalkyl, haloalkoxy, alkenyl, alkynyl, and alkylenyl is unsubstituted; and
with the proviso that the compound is not agelastatin E,,